BR102014031185A8 - recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment - Google Patents

recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment

Info

Publication number
BR102014031185A8
BR102014031185A8 BR102014031185A BR102014031185A BR102014031185A8 BR 102014031185 A8 BR102014031185 A8 BR 102014031185A8 BR 102014031185 A BR102014031185 A BR 102014031185A BR 102014031185 A BR102014031185 A BR 102014031185A BR 102014031185 A8 BR102014031185 A8 BR 102014031185A8
Authority
BR
Brazil
Prior art keywords
protein
obtaining
cancer treatment
recombinant protein
inducing
Prior art date
Application number
BR102014031185A
Other languages
Portuguese (pt)
Other versions
BR102014031185A2 (en
Inventor
Lopes Carvalho André
Eliseo Melendez Matias
Original Assignee
Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp
Hospital De Cancer De Barretos Fund Pio Xii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp, Hospital De Cancer De Barretos Fund Pio Xii filed Critical Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp
Priority to BR102014031185A priority Critical patent/BR102014031185A8/en
Priority to ARP150103744A priority patent/AR102679A1/en
Priority to PCT/BR2015/050244 priority patent/WO2016090448A1/en
Publication of BR102014031185A2 publication Critical patent/BR102014031185A2/en
Publication of BR102014031185A8 publication Critical patent/BR102014031185A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

proteína recombinante; processo de construção da mesma e o uso para o tratamento de disturbios relacionados com a proliferação celular indesejada esta invenção apresenta o processo de construção de uma proteína recombinante pela fusão com o domínio foldon, sendo transfectada e expressa em um vetor não viral. a proteína recombinante é capaz de induzir apoptose celular através da interação com receptores de membrana dr4 e drs, sendo utilizada em tratamento de distúrbios relacionados com a proliferação celular indesejada.recombinant protein; its construction process and its use for the treatment of disorders related to unwanted cell proliferation this invention presents the process of constructing a recombinant protein by fusion with the foldon domain, being transfected and expressed in a non-viral vector. the recombinant protein is able to induce cell apoptosis through interaction with dr4 and drs membrane receptors, being used in the treatment of disorders related to unwanted cell proliferation.

BR102014031185A 2014-12-12 2014-12-12 recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment BR102014031185A8 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR102014031185A BR102014031185A8 (en) 2014-12-12 2014-12-12 recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment
ARP150103744A AR102679A1 (en) 2014-12-12 2015-11-17 RECOMBINING PROTEIN; PROCESS OF CONSTRUCTION OF THE SAME AND USE FOR THE TREATMENT OF DISTURBES RELATED TO THE ANOMAL CELL PROLIFERATION
PCT/BR2015/050244 WO2016090448A1 (en) 2014-12-12 2015-12-10 Recombinant protein, method for constructing the same and use for treating disorders associated with undesirable cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102014031185A BR102014031185A8 (en) 2014-12-12 2014-12-12 recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment

Publications (2)

Publication Number Publication Date
BR102014031185A2 BR102014031185A2 (en) 2016-06-14
BR102014031185A8 true BR102014031185A8 (en) 2021-05-04

Family

ID=56106331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102014031185A BR102014031185A8 (en) 2014-12-12 2014-12-12 recombinant apoptosis-inducing protein; process of obtaining said protein and its use in cancer treatment

Country Status (3)

Country Link
AR (1) AR102679A1 (en)
BR (1) BR102014031185A8 (en)
WO (1) WO2016090448A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
JP2010503418A (en) * 2006-09-19 2010-02-04 ドイチェス クレープスフォルシュングスツェントルム In vivo and in vitro regulation of neurogenesis in adult neural stem cells by the cell death receptor CD95
PL391627A1 (en) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Anticancer fusion protein

Also Published As

Publication number Publication date
BR102014031185A2 (en) 2016-06-14
WO2016090448A1 (en) 2016-06-16
AR102679A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
CL2018003406A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof.
BR112016029906A2 (en) viscosity reducing excipient compounds for protein formulations
NI201600164A (en) COMPOUNDS AND COMPOSITIONS AS AGONISTS OF THE TOLL 7 TYPE RECEPTOR
BR112018012180A2 (en) virus encoding an anti-tcr antibody or fragment
CL2017001289A1 (en) Fused bicyclic compounds, their compositions and their use for the treatment of diseases related to the modulation of the x-farnesoid receptor (fxr).
CL2019000729A1 (en) Recombinant binding proteins and their uses.
SV2017005425A (en) COAGONISTS OF GLUCAGON AND GLP-1 "RECEIVERS
BR112018008865A8 (en) cd80 extracellular domain polypeptides and their use in cancer treatment
CR20150664A (en) MODULATORS OF ESTROGEN RECEIVERS AND THEIR USES
DK3308793T3 (en) THERAPEUTIC AGENT FOR SKIN WOUNDS OR RUDE SKIN
CL2014003572A1 (en) Compounds derived from aryl-sultam or a salt thereof, as modulators of the function of the orphan receptor rorc; composition that contains them; and its use for the treatment or prophylaxis of arthritis.
DOP2015000246A (en) DERIVATIVES OF REPLACED OXOPIRIDINE AND USES OF THE SAME IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
BR112016020368A2 (en) multimeric fc proteins
CL2016001840A1 (en) Compounds derived from fused pyrimidines as inhibitors of the p97 complex; Pharmaceutical composition and use in cancer treatment.
BR112015021866A2 (en) GLA DOMAINS AS DRIVING AGENTS
UY35425A (en) COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN
UY35426A (en) COMPOUNDS AND THEIR USES IN THE MODULATION OF HEMOGLOBIN
DK3319963T3 (en) SUBSTITUTED 4-AZA INDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
MX2020004801A (en) Bispecific fusion polypeptides and methods of use thereof.
BR112017009792A2 (en) anti-pdgf-b antibodies and methods of use
NZ764154A (en) New cath2 derivatives
DK3313464T3 (en) TISSUE MANIPULATION TEMPLATES INCLUDING PARTICULAR EGG SHELL MEMBRANE
DK3253208T3 (en) Combination therapies for use in the treatment of breast cancer
CY1124057T1 (en) X HEPATO RECEIVER MODULATORS (LXR)
BR112017016435A2 (en) co2-containing beverage barrel and use

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: HOSPITAL DE CANCER DE BARRETOS - FUNDACAO PIO XII

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2371 DA RPI 14/06/2016, QUANTO AO ITEM 54

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]